190.95 USD
+3.13
1.67%
At close May 15, 4:00 PM EDT
After hours
191.00
+0.05
0.03%
1 day
1.67%
5 days
-1.73%
1 month
0.54%
3 months
-6.64%
6 months
-17.16%
Year to date
-16.91%
1 year
-27.52%
5 years
16.54%
10 years
191.35%
 

About: In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Then, through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life science and diagnostic industries after the late 2023 divestiture of its environmental and applied solutions group, Veralto.

Employees: 63,000

0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 9 analysts

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

76% more call options, than puts

Call options by funds: $1.78B | Put options by funds: $1.01B

28% more first-time investments, than exits

New positions opened: 250 | Existing positions closed: 196

1.38% more ownership

Funds ownership: 77.6% [Q3] → 78.99% (+1.38%) [Q4]

1% more funds holding

Funds holding: 2,242 [Q3] → 2,262 (+20) [Q4]

16% less capital invested

Capital invested by funds: $156B [Q3] → $131B (-$24.6B) [Q4]

18% less repeat investments, than reductions

Existing positions increased: 766 | Existing positions reduced: 933

42% less funds holding in top 10

Funds holding in top 10: 97 [Q3] → 56 (-41) [Q4]

Research analyst outlook

9 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$215
13%
upside
Avg. target
$241
26%
upside
High target
$260
36%
upside

9 analyst ratings

positive
100%
neutral
0%
negative
0%
RBC Capital
Conor McNamara
15% 1-year accuracy
6 / 41 met price target
31%upside
$250
Outperform
Reiterated
23 Apr 2025
Goldman Sachs
Matthew Sykes
43% 1-year accuracy
15 / 35 met price target
26%upside
$240
Buy
Maintained
23 Apr 2025
Guggenheim
Subbu Nambi
39% 1-year accuracy
9 / 23 met price target
31%upside
$250
Buy
Reiterated
23 Apr 2025
UBS
Dan Leonard
62% 1-year accuracy
8 / 13 met price target
26%upside
$240
Buy
Maintained
23 Apr 2025
Baird
Catherine Schulte
22% 1-year accuracy
4 / 18 met price target
18%upside
$225
Outperform
Maintained
23 Apr 2025

Financial journalist opinion

Based on 19 articles about DHR published over the past 30 days

Neutral
Seeking Alpha
8 hours ago
Danaher Corporation (DHR) BofA Securities 2025 Healthcare Conference (Transcript)
Danaher Corporation (NYSE:DHR ) BofA Securities 2025 Healthcare Conference May 15, 2025 1:00 PM ET Company Participants Rainer Blair - CEO Conference Call Participants Mike Ryskin - Bank of America Mike Ryskin My name is Mike Ryskin. I'm on the Bank of America Life Science Tools and Diagnostics team and I'm excited to host our next session.
Danaher Corporation (DHR) BofA Securities 2025 Healthcare Conference (Transcript)
Positive
Zacks Investment Research
6 days ago
CVS vs. DHR: Which Stock Is the Better Value Option?
Investors looking for stocks in the Medical Services sector might want to consider either CVS Health (CVS) or Danaher (DHR). But which of these two companies is the best option for those looking for undervalued stocks?
CVS vs. DHR: Which Stock Is the Better Value Option?
Neutral
PRNewsWire
1 week ago
Danaher to Present at Bank of America Securities Healthcare Conference
WASHINGTON , May 7, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the at the Bank of America Securities Health Care Conference in Las Vegas, Nevada on Thursday, May 15, 2025 at 10:00 a.m.
Danaher to Present at Bank of America Securities Healthcare Conference
Neutral
PRNewsWire
1 week ago
Danaher Announces Quarterly Dividend
WASHINGTON , May 6, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.32 per share of its common stock, payable on July 25, 2025 to holders of record on June 27, 2025. ABOUT DANAHER Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health.
Danaher Announces Quarterly Dividend
Positive
Seeking Alpha
1 week ago
Danaher: A Capital Intensive Business Offering Low Risk, Low Reward Opportunity
Danaher Corporation's intrinsic value is estimated at $213 per share, suggesting a 14% upside from the current price of $187, with a 12% margin of safety. Despite revenue growth driven by acquisitions, Danaher's heavy reliance on debt and declining ROIC indicate challenges in capital efficiency and operational performance. The company's high capital intensity, slow growth, and mounting debt levels make its near-term investment potential pessimistic, despite a diversified portfolio.
Danaher: A Capital Intensive Business Offering Low Risk, Low Reward Opportunity
Negative
Seeking Alpha
1 week ago
Danaher: Q1 Beat Fails To Trigger Guidance Upgrade
Danaher's management appears to be strategically keeping the stock price depressed to complete its share buyback program and capitalize on lower acquisition target valuations. The company delivered better-than-expected Q1 2025 results, driven by strong performance in biotechnology and molecular diagnostics, despite maintaining conservative guidance. DHR has repurchased 4.5 million shares this year, with 12 million more to go, aligning with their strategy of benefiting from a lower stock price.
Danaher: Q1 Beat Fails To Trigger Guidance Upgrade
Positive
Seeking Alpha
2 weeks ago
Baron Health Care Fund Q1 2025 Top Contributors And Detractors
Boston Scientific's shares rose due to strong market growth, innovative products like pulsed field ablation, and disciplined cost management, driving double-digit EPS growth. Vertex Pharmaceuticals saw increased investor confidence in its cystic fibrosis franchise and evolving pipeline, including promising non-opioid pain treatments and kidney disease drugs. UnitedHealth Group's shares gained as 2024 headwinds subsided, Medicare Advantage rates improved, and higher-margin Optum segments grew, insulating it from tariff impacts.
Baron Health Care Fund Q1 2025 Top Contributors And Detractors
Neutral
PRNewsWire
2 weeks ago
Kytopen and Aldevron Expedite Cell Therapy Manufacturing Through Their Collaborative CRISPR-mediated Cellular Engineering Workflow
Kytopen and Aldevron announce collaboration to expedite cell therapy manufacturing by combining their novel technologies. High transgene expression and improved safety profile of Aldveron's Nanoplasmid™  vector technology and the gentle gene-delivery of Kytopen's Flowfect Tx™ platform with unlimited scale, together offer enhanced CRISPR-mediated T-cell engineering resulting in high yields.
Kytopen and Aldevron Expedite Cell Therapy Manufacturing Through Their Collaborative CRISPR-mediated Cellular Engineering Workflow
Positive
Zacks Investment Research
3 weeks ago
BLCO or DHR: Which Is the Better Value Stock Right Now?
Investors interested in stocks from the Medical Services sector have probably already heard of Bausch + Lomb (BLCO) and Danaher (DHR). But which of these two stocks presents investors with the better value opportunity right now?
BLCO or DHR: Which Is the Better Value Stock Right Now?
Neutral
Zacks Investment Research
3 weeks ago
Danaher Q1 Earnings Beat Estimates, Life Sciences Sales Down Y/Y
DHR's first-quarter sales decrease 1% year over year, due to the lackluster performance of its Life Sciences and Biotechnology segments.
Danaher Q1 Earnings Beat Estimates, Life Sciences Sales Down Y/Y
Charts implemented using Lightweight Charts™